Aller au contenu principal
Accès ouvert déclaré 2026 article

AMPK-mediated prevention of vascular dysfunction with metformin: Experimental and population-based evidence

0Citations signalées — pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND AND PURPOSE: Metformin is increasingly recognised for its vasculoprotective effects, primarily through activation of AMP-activated protein kinase (AMPK). We combined population-based genetic epidemiology, with an ex vivo vascular model, to investigate the beneficial vascular effects of AMPK activation by metformin. EXPERIMENTAL APPROACH: We used genetically proxied AMPK activation (GP-AMPK), based on 20 genome-wide significant single-nucleotide polymorphisms (SNPs), to assess associations with pulse wave velocity (PWV) and carotid intima-media thickness (cIMT). A two-sample Mendelian randomisation (MR) was performed to test the effect of GP-AMPK on a panel of inflammatory markers. We also developed a porcine coronary artery model of endothelial dysfunction to test the restorative effects of metformin on vascular function and related molecular signalling pathways. KEY RESULTS: Higher GP-AMPK activation was associated with lower PWV, but not cIMT, in our epidemiological analysis (mean age 64.3 years, 43.8% female). Ex vivo, metformin restored endothelial relaxation in Angiotensin (Ang) II-treated vessels via endothelium-dependent hyperpolarisation (EDH) mechanisms, an effect abolished by AMPK inhibition. Western blotting confirmed the activation of AMPK (alpha 1 subunit) with metformin treatment. Inhibitor studies demonstrated a shift from NO-mediated to EDH-mediated relaxation with metformin. Molecular analyses showed reduced Ang II-induced expression of matrix remodelling (MMP1, MMP2) and senescence (P21) markers, as well as suppression of pro-inflammatory cytokines (Il-1β, Il-6, TNF-α), consistent with MR results. CONCLUSION AND IMPLICATIONS: Metformin restored endothelial function and reduced vascular stiffness through an AMPK-EDH axis, highlighting a novel, potential therapeutic mechanism for early vascular dysfunction independent of glycaemic effects.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

Aucun DOI disponible pour le contrôle Crossref.

Sujets associés

Metabolism, Diabetes, and CancerCardiovascular Health and Disease PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.